Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of rapcabtagene autoleucel versus rituximab in severe refractory diffuse systemic sclerosis
MOH_2024-11-14_013735Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in systemic sclerosis (SSc) comparing YTB323 treatment arm with Rituximab treatment arm (2 arms). Started Nov 2024; status: recruiting.
02
Drugs
rapcabtagene autoleucelrituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2024-11-14_013735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-11-14_013735.